Arpida Announces FDA Acceptance of the Iclaprim New Drug Application May 16, 2008
Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages. (PR Newswire)
Barrier Therapeutics Announces Positive Results in Reducing Itch Symptoms With Novel Oral Antihistamine Agent Hivenyl Apr 9, 2008
Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and superficial fungal infections. The company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. (Primezone Releases)
Barrier Therapeutics Announces Positive Results of Dose Escalation Clinical Safety Study With Pramiconazole Nov 27, 2007
The total of 6 grams administered over five days is 30 times higher than the single weekly dose of 200 mg of pramiconazole that is being used in a Phase 2a study in toenail onychomycosis (nail fungus) currently underway in Europe ... When we consider these data along with previously reported clinical efficacy results in onychomycosis and other fungal infections, we continue to believe there is a strong clinical rationale for advancing this product candidate to the next stage of development ...... (Primezone Releases)
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim Nov 21, 2007
Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis. Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages. (PR Newswire)
Macrochem acquires option to license pexiganan Jul 11, 2007
This trial was specifically designed, with the assistance of well-known onychomycosis experts, to address three important objectives: to assess early signs of efficacy, to maintain robust clinical endpoints in the full study, and, if successful, to facilitate advancement to Phase 3 as soon as possible. . (EurekAlert! -- Business News)
Schering-Plough, Anacor ink deal Feb 5, 2007
-based Anacor said the agreement with New Jersey-based Schering-Plough covers development and commercialization of the drug, which is currently in phase 2 clinical trials for onychomycosis, a fungal infection of the nail and nail bed ... Schering-Plough will assume all costs for the drug's development for onychomycosis and other indications, and Anacor retains an option to co-promote the drug in the U.S. to dermatologists. (Memphis Business Journal, TN)
What is toenail fungus and what's the best way to get rid of it? Nov 7, 2006
Toenail fungus, or onychomycosis, is common, affecting 3 percent to 5 percent of Americans. It can start with simple athlete's foot, a fungal infection that if untreated can lead to infection deep into the nail matrix, from which the nail grows. (Boston Globe)
[extra: Longer version] Jul 14, 2006
At the other end of the scale cheap treatments may also be excluded if the conditions they treat are not serious enough, such as colds or onychomycosis. The council also proposes a second step in which wider society could say whether such decisions are justified. (British Medical Journal)
Gross profits from eww effect May 5, 2006
com, potential customers can learn about the nail fungus infection called "onychomycosis" and also read a detailed story about how Digger made himself comfy under a victims toenails even as over-the-counter medicines failed to work. "Im outta here," he says finally after being defeated by Lamisil. (Seacoast New Hampshire)
Ads push boundaries of good taste Apr 25, 2006
On the company's Web site, potential customers can learn about the nail fungus infection called onychomycosis and also read a detailed story about how Digger made himself comfy under a victim's toenails even as over-the-counter medicines failed to work. "The campaign has been successful," said Joan Harmeyer, a Novartis spokeswoman. (AZCentral -- Business)
